Y-mAbs Therapeutics, Inc.
NASDAQ:YMAB
15.55 (USD) • At close November 7, 2024
Overzicht | Financiële gegevens
Cijfers zijn in miljoenen (behalve de cijfers per aandeel en de ratio's) USD.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|
| Omzet
| 84.819 | 65.267 | 34.897 | 20.75 | 0 | 0 | 0 | 0 |
| Kosten van de omzet
| 11.416 | 7.567 | 2.514 | 2.203 | 0.166 | 0.029 | 0 | 0 |
| Brutowinst
| 73.403 | 57.7 | 32.383 | 18.547 | -0.166 | -0.029 | 0 | 0 |
| Brutowinstmarge
| 0.865 | 0.884 | 0.928 | 0.894 | 0 | 0 | 0 | 0 |
| Onderzoek- en ontwikkelingskosten
| 50.873 | 91.572 | 93.245 | 93.697 | 63.492 | 34.269 | 14.307 | 13.855 |
| Algemene en administratieve kosten
| 0 | 0 | 0 | 44.785 | 19.512 | 8.961 | 4.937 | 3.184 |
| Verkoop- en marketingkosten
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Verkoop-, algemene en administratieve kosten
| 43.72 | 60.939 | 54.571 | 44.785 | 19.512 | 8.961 | 4.937 | 3.184 |
| Overige kosten
| 0.356 | 0 | 62.01 | -2.203 | 0 | -0.044 | 0.083 | -0.018 |
| Bedrijfskosten
| 94.593 | 152.511 | 147.816 | 138.482 | 83.004 | 43.23 | 19.244 | 17.039 |
| Bedrijfsresultaat
| -21.19 | -94.811 | -115.433 | -119.935 | -83.004 | -43.23 | -19.244 | -17.039 |
| Bedrijfsresultaat ratio
| -0.25 | -1.453 | -3.308 | -5.78 | 0 | 0 | 0 | 0 |
| Totaal overige inkomsten en kosten netto
| 0.324 | -0.757 | 60.158 | 0.598 | 1.976 | -0.044 | 0.083 | -0.018 |
| Inkomen voor belasting
| -20.866 | -95.568 | -55.275 | -119.337 | -81.028 | -43.274 | -19.161 | -17.057 |
| Inkomen voor belasting ratio
| -0.246 | -1.464 | -1.584 | -5.751 | 0 | 0 | 0 | 0 |
| Belastingkosten
| 0.561 | 0.757 | 1.07 | -0.994 | -2.142 | -0.044 | -19.244 | -17.039 |
| Nettowinst
| -21.427 | -96.325 | -56.345 | -118.343 | -78.886 | -43.274 | -19.161 | -17.057 |
| Nettowinstmarge
| -0.253 | -1.476 | -1.615 | -5.703 | 0 | 0 | 0 | 0 |
| WPA (Winst Per Aandeel)
| -0.49 | -2.2 | -1.3 | -2.95 | -2.24 | -1.5 | -0.58 | -0.51 |
| Verwaterde WPA
| -0.49 | -2.2 | -1.3 | -2.95 | -2.24 | -1.5 | -0.58 | -0.51 |
| EBITDA
| -20.455 | -94.811 | -115.433 | -117.732 | -83.004 | -43.23 | -19.244 | -17.039 |
| EBITDA ratio
| -0.241 | -1.453 | -3.308 | -5.674 | 0 | 0 | 0 | 0 |